Hirtle Callaghan Trust
Growth Portfolio
Jennison Associates
Procedures Pursuant to 10f-3
Securities Purchased Comparable Securities (1)
1 Underwriter(s) (See prospectus) Refer to Attached Refer to
Attached
2 Name of Issuer "Roche Holdings, Inc." "Pharmacyclics, Inc."
3 Title of Security "Genentech, Inc." "Pharmacyclics, Inc."
4 Date of Offering 10/20/99 9/23/99
5 Amount of offering "$2,870,000,000.00 " "$89,125,000.00 "
6 Unit Price $143.50 $38.75
7 Underwriting Spread or Commission "$2,655.00 " "$2,230.00 "
8 Ratings N/A N/A
9 Maturity Date N/A N/A
10 Curent yield N/A N/A
11 Yield to Maturity N/A N/A
12 Subordinate Features N/A N/A
13 "Nature of issuing Political Entity, if any, including in case of
Revenue Bonds,
underlying entity supplying the revenue" N/A N/A
14 Total par value of Bonds purchased N/A N/A
15 Dollar amount of Purchases "$459,200.00 " N/A
16 Number of Shares Purchased 3200 N/A
17 Years of Continuous Operartions >3 >3
18 Percentage of Offering Purchaed by Portfolio 0.016% N/A
19 Percentage of Portfolio Purchaed by other Portfolios of the Funds
and Investment
Companies advised by the Adviser or any Subadviser *
20 Percentage of Portfolio Assets Applied to purchase 0.242% **
21 Name(s) of Underwriter(s) or Dealer(s) from whom purchased
JP Morgan
22 "Is the Adviser or Subadviser or any person or which the Adviser or
Subadviser is
an ""affiliated person"", a Manager or Co-manager of the Offerings?" NO
23 "Were Purchases designated as Group Sales or otherwise allocated to
adviser,
an subadviser or any person of whom the Adviser or Subadviser is an
""Affiliated Person""?" NO
* Jennison received approximately 2.5% of the offering to allocate
amongst
its client accounts.
** This applies only to the portion of the assets managed by Jennison.
